vs
Side-by-side financial comparison of Confluent, Inc. (CFLT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Confluent, Inc. is the larger business by last-quarter revenue ($314.8M vs $177.4M, roughly 1.8× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -25.2%, a 26.8% gap on every dollar of revenue. On growth, Confluent, Inc. posted the faster year-over-year revenue change (20.5% vs 5.0%). Over the past eight quarters, Confluent, Inc.'s revenue compounded faster (20.4% CAGR vs -0.2%).
Confluent, Inc. is an American technology company headquartered in Mountain View, California. Confluent was founded by Jay Kreps, Jun Rao and Neha Narkhede on September 23, 2014, in order to commercialize an open-source streaming platform Apache Kafka, created by the same founders while working at LinkedIn in 2008 as a B2B infrastructure company. Confluent's products are the Confluent Cloud, Confluent Platform, Connectors, Apache Flink, Stream Governance and Confluent Hub.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CFLT vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $314.8M | $177.4M |
| Net Profit | $-79.2M | $2.9M |
| Gross Margin | 74.7% | — |
| Operating Margin | -31.5% | 3.9% |
| Net Margin | -25.2% | 1.6% |
| Revenue YoY | 20.5% | 5.0% |
| Net Profit YoY | 10.0% | — |
| EPS (diluted) | $-0.23 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $314.8M | $196.9M | ||
| Q3 25 | $298.5M | $179.5M | ||
| Q2 25 | $282.3M | $181.1M | ||
| Q1 25 | $271.1M | $168.9M | ||
| Q4 24 | $261.2M | $187.3M | ||
| Q3 24 | $250.2M | $168.6M | ||
| Q2 24 | $235.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-79.2M | — | ||
| Q3 25 | $-66.5M | $5.4M | ||
| Q2 25 | $-82.0M | $-4.8M | ||
| Q1 25 | $-67.6M | $4.8M | ||
| Q4 24 | $-88.1M | — | ||
| Q3 24 | $-74.1M | $-143.5M | ||
| Q2 24 | $-89.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 74.7% | 79.5% | ||
| Q3 25 | 74.2% | 80.9% | ||
| Q2 25 | 73.7% | 77.4% | ||
| Q1 25 | 74.5% | 79.7% | ||
| Q4 24 | 74.1% | 78.7% | ||
| Q3 24 | 74.5% | 76.9% | ||
| Q2 24 | 72.3% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -31.5% | 1.2% | ||
| Q3 25 | -27.9% | 3.5% | ||
| Q2 25 | -34.2% | 4.7% | ||
| Q1 25 | -37.3% | 1.2% | ||
| Q4 24 | -40.5% | 13.2% | ||
| Q3 24 | -37.4% | -82.8% | ||
| Q2 24 | -46.1% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -25.2% | — | ||
| Q3 25 | -22.3% | 3.0% | ||
| Q2 25 | -29.0% | -2.7% | ||
| Q1 25 | -24.9% | 2.8% | ||
| Q4 24 | -33.7% | — | ||
| Q3 24 | -29.6% | -85.1% | ||
| Q2 24 | -38.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.23 | $0.05 | ||
| Q3 25 | $-0.19 | $0.12 | ||
| Q2 25 | $-0.24 | $-0.11 | ||
| Q1 25 | $-0.20 | $0.10 | ||
| Q4 24 | $-0.26 | $0.38 | ||
| Q3 24 | $-0.23 | $-3.11 | ||
| Q2 24 | $-0.28 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $347.2M | $144.3M |
| Total DebtLower is stronger | $1.1B | — |
| Stockholders' EquityBook value | $1.2B | $653.9M |
| Total Assets | $3.0B | $1.2B |
| Debt / EquityLower = less leverage | 0.94× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $347.2M | $238.4M | ||
| Q3 25 | $298.5M | $246.3M | ||
| Q2 25 | $295.6M | $445.9M | ||
| Q1 25 | $278.6M | $493.6M | ||
| Q4 24 | $386.0M | $484.6M | ||
| Q3 24 | $322.6M | $453.8M | ||
| Q2 24 | $311.3M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $372.2M | ||
| Q3 25 | $1.1B | $376.7M | ||
| Q2 25 | $1.1B | $580.5M | ||
| Q1 25 | $1.1B | $583.4M | ||
| Q4 24 | $1.1B | $585.3M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.2B | $693.1M | ||
| Q3 25 | $1.1B | $727.2M | ||
| Q2 25 | $1.1B | $757.8M | ||
| Q1 25 | $1.0B | $798.5M | ||
| Q4 24 | $961.2M | $778.3M | ||
| Q3 24 | $934.3M | $749.6M | ||
| Q2 24 | $873.9M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $3.0B | $1.3B | ||
| Q3 25 | $2.9B | $1.3B | ||
| Q2 25 | $2.8B | $1.5B | ||
| Q1 25 | $2.7B | $1.6B | ||
| Q4 24 | $2.7B | $1.6B | ||
| Q3 24 | $2.6B | $1.5B | ||
| Q2 24 | $2.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.94× | 0.54× | ||
| Q3 25 | 0.98× | 0.52× | ||
| Q2 25 | 1.03× | 0.77× | ||
| Q1 25 | 1.07× | 0.73× | ||
| Q4 24 | 1.14× | 0.75× | ||
| Q3 24 | 1.17× | — | ||
| Q2 24 | 1.25× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | — |
| Free Cash FlowOCF − Capex | $41.7M | — |
| FCF MarginFCF / Revenue | 13.2% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $60.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $43.7M | ||
| Q3 25 | $30.8M | $60.8M | ||
| Q2 25 | $18.1M | $12.0M | ||
| Q1 25 | $-26.8M | $35.5M | ||
| Q4 24 | $35.2M | $33.1M | ||
| Q3 24 | $15.6M | $53.9M | ||
| Q2 24 | $8.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $41.7M | $43.5M | ||
| Q3 25 | $30.0M | $57.0M | ||
| Q2 25 | $17.2M | $9.3M | ||
| Q1 25 | $-28.2M | $26.9M | ||
| Q4 24 | $34.5M | $31.0M | ||
| Q3 24 | $15.0M | $49.8M | ||
| Q2 24 | $7.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 13.2% | 22.1% | ||
| Q3 25 | 10.0% | 31.7% | ||
| Q2 25 | 6.1% | 5.1% | ||
| Q1 25 | -10.4% | 15.9% | ||
| Q4 24 | 13.2% | 16.6% | ||
| Q3 24 | 6.0% | 29.6% | ||
| Q2 24 | 3.2% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.3% | 2.2% | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.5% | 5.1% | ||
| Q4 24 | 0.3% | 1.1% | ||
| Q3 24 | 0.2% | 2.4% | ||
| Q2 24 | 0.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFLT
| Confluent Cloud | $169.4M | 54% |
| Post Contract Customer Support | $93.8M | 30% |
| License | $38.4M | 12% |
| Services | $13.2M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
